PTC Therapeutics Inc (STU:BH3)
€ 68.32 -2.96 (-4.15%) Market Cap: 5.68 Bil Enterprise Value: 4.37 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 52/100

PTC Therapeutics Inc at Citi Global Healthcare Conference Transcript

Dec 04, 2025 / 03:30PM GMT
Release Date Price: €63.5 (-3.79%)
Geoffrey Meacham;Douala Branch;Analyst
Citibank Cameroon SA

()-

Conference, my name's Geoff Meacham. I'm the senior biopharma analyst here, and I have Jarway Fang from my team on here as well. We're thrilled today to have PTC Therapeutics. With us on stage is Matt Klein, CEO. Matt, welcome.

Matthew Klein
PTC Therapeutics Inc - Chief Executive Officer, Director

Good to see you. Great to be here.

Geoffrey Meacham;Douala Branch;Analyst
Citibank Cameroon SA

()-

So, lots of questions on Safiance and on your R&D day, but maybe just for those on the webcast, just give us, a bit of a quick background or overall, and then we can get right into it.

Matthew Klein
PTC Therapeutics Inc - Chief Executive Officer, Director

Yeah, absolutely. So PTC is a global biopharmaceutical company. We are focused on rare diseases and other disorders of high unmet need. We have a robust, commercial portfolio with 6 products that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot